Difference between revisions of "Ranitidine"
(→Contraindications) |
|||
(8 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
− | *Type: H2 | + | *Type: [[H2 blocker]] |
*Dosage Forms: 75, 150, 300 | *Dosage Forms: 75, 150, 300 | ||
*Common Trade Names: Zantac | *Common Trade Names: Zantac | ||
==Adult Dosing== | ==Adult Dosing== | ||
− | GERD: | + | GERD: 150mg PO BID |
==Pediatric Dosing== | ==Pediatric Dosing== | ||
− | GERD: 5- | + | GERD: 5-10mg/kg/day PO BID |
==Special Populations== | ==Special Populations== | ||
Line 14: | Line 14: | ||
*Lactation: Probably Safe | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
− | **Adult: CrCl < 50: | + | **Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis |
**Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | **Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | ||
*Hepatic Dosing | *Hepatic Dosing | ||
Line 22: | Line 22: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
− | * Porphyria | + | *Porphyria |
− | * | + | *Caution if impairment of liver or kidneys |
− | * | + | *Caution in chronic pulmonary disease |
− | + | *Caution if diabetes mellitus | |
− | * | + | *Caution if immunocompromised |
− | * | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
+ | *Thrombocytopenia | ||
+ | *Hepatotoxicity | ||
+ | *[[Pneumonia]] | ||
===Common=== | ===Common=== | ||
+ | *Nausea/vomiting/diarrhea | ||
+ | *Fatigue | ||
+ | *Headache | ||
+ | *Rash | ||
+ | *Myalgia | ||
+ | *Xerostomia | ||
==Pharmacology== | ==Pharmacology== | ||
− | *Half-life: | + | *Half-life: 2-3 hr, Renal impairment: 5 hr |
− | *Metabolism: | + | *Metabolism: Liver |
− | *Excretion: | + | *Excretion: Urine, Feces |
− | *Mechanism of Action: | + | *Mechanism of Action: H2 blocker |
==See Also== | ==See Also== | ||
− | |||
+ | ==References== | ||
<references/> | <references/> | ||
− | [[Category: | + | |
+ | [[Category:Pharmacology]] |
Latest revision as of 06:41, 13 July 2017
Contents
General
- Type: H2 blocker
- Dosage Forms: 75, 150, 300
- Common Trade Names: Zantac
Adult Dosing
GERD: 150mg PO BID
Pediatric Dosing
GERD: 5-10mg/kg/day PO BID
Special Populations
- Pregnancy Rating: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis
- Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis
- Hepatic Dosing
- Adult: Not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Porphyria
- Caution if impairment of liver or kidneys
- Caution in chronic pulmonary disease
- Caution if diabetes mellitus
- Caution if immunocompromised
Adverse Reactions
Serious
- Thrombocytopenia
- Hepatotoxicity
- Pneumonia
Common
- Nausea/vomiting/diarrhea
- Fatigue
- Headache
- Rash
- Myalgia
- Xerostomia
Pharmacology
- Half-life: 2-3 hr, Renal impairment: 5 hr
- Metabolism: Liver
- Excretion: Urine, Feces
- Mechanism of Action: H2 blocker